This test is most useful if any of these apply to you.
Vitamin B6 quietly runs hundreds of reactions in your body, from making brain chemical messengers to processing protein. Standard blood panels almost never check it, so most people have no idea whether they are getting enough or, just as importantly, whether their body is chewing through it faster than normal.
Urinary 4-pyridoxic acid (PA, the main waste product of vitamin B6) gives you a window into both questions. It rises when you eat more B6 and falls when intake drops, and it shifts in ways that mirror what is happening in your kidneys, your gut, and your inflammation level.
Vitamin B6 comes in several related forms (collectively called vitamers). Your liver converts them into the active form (pyridoxal 5-phosphate, or PLP), which your cells use to power chemical reactions. After PLP does its job, your body breaks it down into 4-pyridoxic acid and sends it out through your urine.
In healthy adults, 4-pyridoxic acid is the dominant form of vitamin B6 found in urine, with other B6 forms appearing in much smaller amounts. That makes it the cleanest single readout of what your body is doing with this vitamin.
Research in healthy adults shows that the 4-pyridoxic acid to creatinine ratio in a random urine sample tracks closely with a full 24-hour collection. You do not need an all-day collection to get a useful number.
B6 status is not just about intake. It is also about how fast your body uses the vitamin up. Researchers track this using a ratio called PAr, which compares 4-pyridoxic acid to the active form of B6 (PLP). A high ratio means your body is burning through B6 quickly, often because of inflammation or chronic immune activation.
Most of the long-term outcome research uses blood measurements (plasma PLP and plasma 4-pyridoxic acid) rather than urine. The patterns are still informative for understanding what your urinary 4-pyridoxic acid result might signal, but the direct evidence linking urine PA alone to long-term outcomes is more limited.
In a study of 4,881 older adults, lower serum vitamin B6 and a higher vitamin B6 turnover rate were both associated with greater risk of dying from cardiovascular disease and from any cause. A larger study of more than 15,000 US adults found similar patterns: higher vitamin B6 turnover predicted greater mortality risk in the general population.
These signals come from blood-based markers, not urine. Whether urinary 4-pyridoxic acid alone carries the same predictive power has not been directly shown. The takeaway: B6 turnover, however you measure it, looks like a meaningful signal for cardiometabolic health.
The Hordaland Health Study tracked 6,539 adults and found that higher plasma PAr (vitamin B6 turnover) predicted higher overall cancer risk, especially lung cancer. The researchers attributed this to increased B6 breakdown driven by chronic inflammation, a pathway that connects to many chronic diseases.
A meta-analysis of vitamin B6 and cancer risk found that higher dietary B6 intake and higher blood PLP were tied to lower overall cancer risk, particularly gastrointestinal cancers. None of these studies used urinary 4-pyridoxic acid as their primary marker, so the direct urine-to-cancer link is more of a working hypothesis than established evidence.
An analysis of 8,063 US adults from NHANES found that a high serum 4-pyridoxic acid to PLP ratio was associated with higher odds of liver fibrosis, while higher PLP alone was linked to lower fibrosis odds. The signal held across age and coexisting condition subgroups.
Liver fibrosis means scar tissue is building up in your liver, often silently. This finding suggests that the way your body handles vitamin B6 may carry information about liver health beyond standard liver enzymes.
4-pyridoxic acid is cleared from your blood by a specific transporter in your kidneys called OAT3 (organic anion transporter 3). More than 80% of pyridoxic acid's renal clearance runs through this single channel, which makes the molecule one of the cleanest natural markers of how your kidneys handle drug-like substances.
In the CRIC study, a large prospective look at 3,416 adults with chronic kidney disease, lower kidney clearance of several secretory solutes including pyridoxic acid was associated with higher risk of CKD progression, independent of standard kidney markers like eGFR and albumin in urine. The kidney does more than just filter, and pyridoxic acid clearance captures part of that hidden function.
A study of 172 adults found that people with type 2 diabetes had a higher proportion of vitamin B6 excreted as pyridoxic acid compared to controls without diabetes. Both increased B6 breakdown and altered kidney handling contributed.
Among 2,574 people with type 2 diabetes, those with low PLP and high 4-pyridoxic acid in blood had the worst long-term survival. A higher 4-PA to PLP ratio predicted long-term mortality in this group, independent of inflammation and kidney markers.
Vitamin B6 breakdown product levels in urine shift with intake, hormonal cycles, kidney function, and inflammation. In healthy women, 4-pyridoxic acid follows a menstrual-cycle rhythm, dropping around ovulation alongside other metabolic products. Sex differences also show up in healthy populations, with women excreting more pyridoxic acid than men in some cohorts.
Because of this normal variation, a single reading is a snapshot, not a trend. The most useful approach is a baseline test, a follow-up at 3 to 6 months if you are changing your diet or starting a supplement, and at least annual retesting after that. Tracking your own number over time is more meaningful than comparing it to a population range, especially because this biomarker does not yet have standardized clinical cutpoints.
An unexpected high or low does not mean a diagnosis. It means a closer look. If urinary 4-pyridoxic acid looks unusually low and you are not deliberately limiting B6, consider whether your diet is genuinely thin on B6-rich foods (fish, poultry, potatoes, bananas, chickpeas) and whether digestion, absorption, or kidney function might be muting the signal.
If your level looks unusually high, especially relative to your intake, the question is whether something is driving accelerated B6 turnover. Pairing this test with high-sensitivity C-reactive protein (a general inflammation marker), homocysteine (a B-vitamin pathway marker), and kidney function tests like cystatin C and eGFR can quickly clarify whether inflammation, kidney handling, or supplementation is the explanation.
If you are also taking a B6 supplement at higher than typical doses, this is a useful moment to check in with a physician about the dose. Very high chronic B6 intake has been linked to peripheral nerve symptoms, and a high urinary 4-pyridoxic acid in a supplementing person is one early signal worth taking seriously.
Urinary 4-pyridoxic acid is a research-grade biomarker, not a settled clinical test. Standardized cutpoints do not yet exist for individual decision-making, and a single reading should not drive major clinical conclusions on its own. Where it shines is as part of a panel and as a serial track over time, especially for people optimizing nutrition, managing chronic inflammation, or watching their kidney health.
Evidence-backed interventions that affect your Pyridoxic Acid level
Pyridoxic Acid is best interpreted alongside these tests.
Pyridoxic Acid is included in these pre-built panels.